| Stereochemistry | RACEMIC |
| Molecular Formula | C15H18Cl2N4O3 |
| Molecular Weight | 373.234 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CNCCNC1=C(Cl)C(=O)NN=C1)COC2=C(Cl)C=CC=C2
InChI
InChIKey=UUWABVCZFXKHSU-UHFFFAOYSA-N
InChI=1S/C15H18Cl2N4O3/c16-11-3-1-2-4-13(11)24-9-10(22)7-18-5-6-19-12-8-20-21-15(23)14(12)17/h1-4,8,10,18,22H,5-7,9H2,(H2,19,21,23)
| Molecular Formula | C15H18Cl2N4O3 |
| Molecular Weight | 373.234 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Ridazolol is a cardioselective and vasodilating beta-adrenergic receptor antagonist. It also has moderate alpha-adrenolytic activity (the presence of a heterogeneous population of postjunctional alpha adrenoceptors has been suggested). Ridazolol was investigated for use in arrhythmias and ischaemic heart disorders. In patients with confirmed coronary artery disease and reproducible ST-segment depression, blood pressure and heart rate under exercise were significantly reduced for 5 hours, and improvement of ST-segment depression lasted 1 hour. Ridazolol is well tolerated. This drug is not currently used.
